These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 11673664)

  • 1. A chimeric anti-TNFalpha monoclonal antibody (cA2) in vivo removes TNFalpha-producing cells in Crohn's disease.
    Urra JM; Arteta M; Gómez-Caturla A; García-Durán F
    Hum Antibodies; 2001; 10(2):91-4. PubMed ID: 11673664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.
    Targan SR; Hanauer SB; van Deventer SJ; Mayer L; Present DH; Braakman T; DeWoody KL; Schaible TF; Rutgeerts PJ
    N Engl J Med; 1997 Oct; 337(15):1029-35. PubMed ID: 9321530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of a 99mTc labeled anti-TNFalpha monoclonal antibody in Crohn's disease: in vitro and in vivo studies.
    D'Alessandria C; Malviya G; Viscido A; Aratari A; Maccioni F; Amato A; Scopinaro F; Caprilli R; Signore A
    Q J Nucl Med Mol Imaging; 2007 Dec; 51(4):334-42. PubMed ID: 17464276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term partial remission of autoimmune thrombocytopenia in a patient treated with the anti-tumor necrosis factor-alpha antibody infliximab for refractory fistulizing Crohn's disease.
    de Rossi TM; Krauss N; Voll RE; Nägel A; Weidenhiller M; Konturek PC; Hahn EG; Raithel M
    Digestion; 2008; 78(4):195-200. PubMed ID: 19122456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study.
    Asteria CR; Ficari F; Bagnoli S; Milla M; Tonelli F
    Scand J Gastroenterol; 2006 Sep; 41(9):1064-72. PubMed ID: 16938720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibodies to tumor necrosis factor-alpha in the treatment of Crohn's disease.
    Brown SJ; Abreu MT
    Curr Opin Drug Discov Devel; 2005 Mar; 8(2):160-8. PubMed ID: 15782540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease.
    Bauditz J; Lochs H; Schreiber S
    N Engl J Med; 1998 Jan; 338(5):334. PubMed ID: 9446035
    [No Abstract]   [Full Text] [Related]  

  • 8. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The frequency of sister chromatid exchanges in patients with Crohn's disease and the effect of therapy with "anti-tumor necrosis factor" on this frequency.
    Danalioglu A
    Hepatogastroenterology; 2009; 56(91-92):729-33. PubMed ID: 19621692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD40 and CD86 upregulation with divergent CMRF44 expression on blood dendritic cells in inflammatory bowel diseases.
    Vuckovic S; Florin TH; Khalil D; Zhang MF; Patel K; Hamilton I; Hart DN
    Am J Gastroenterol; 2001 Oct; 96(10):2946-56. PubMed ID: 11693331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions.
    Scallon BJ; Moore MA; Trinh H; Knight DM; Ghrayeb J
    Cytokine; 1995 Apr; 7(3):251-9. PubMed ID: 7640345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
    Martínez-Borra J; López-Larrea C; González S; Fuentes D; Dieguez A; Deschamps EM; Pérez-Pariente JM; López-Vázquez A; de Francisco R; Rodrigo L
    Am J Gastroenterol; 2002 Sep; 97(9):2350-6. PubMed ID: 12358255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).
    van Dullemen HM; van Deventer SJ; Hommes DW; Bijl HA; Jansen J; Tytgat GN; Woody J
    Gastroenterology; 1995 Jul; 109(1):129-35. PubMed ID: 7797011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease.
    Candon S; Mosca A; Ruemmele F; Goulet O; Chatenoud L; Cézard JP
    Clin Immunol; 2006 Jan; 118(1):11-9. PubMed ID: 16125467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment.
    Hyder SA; Travis SP; Jewell DP; McC Mortensen NJ; George BD
    Dis Colon Rectum; 2006 Dec; 49(12):1837-41. PubMed ID: 17041753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic inhibitors of tumor necrosis factor in Crohn's disease.
    Ganesan S; Travis SP; Ahmad T; Jazrawi R
    Curr Opin Investig Drugs; 2002 Sep; 3(9):1301-6. PubMed ID: 12498004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional modulation of Crohn's disease myofibroblasts by anti-tumor necrosis factor antibodies.
    Di Sabatino A; Pender SL; Jackson CL; Prothero JD; Gordon JN; Picariello L; Rovedatti L; Docena G; Monteleone G; Rampton DS; Tonelli F; Corazza GR; MacDonald TT
    Gastroenterology; 2007 Jul; 133(1):137-49. PubMed ID: 17631138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infliximab reduces the number of activated mucosal lymphocytes in patients with Crohn's disease.
    Ferkolj I; Ihan A; Markovic S; Veceric Z; Pohar M
    J Gastrointestin Liver Dis; 2006 Sep; 15(3):231-5. PubMed ID: 17013447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
    Gao Q; Hogezand RA; Lamers CB; Verspaget HW
    Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease.
    Hommes DW; Mikhajlova TL; Stoinov S; Stimac D; Vucelic B; Lonovics J; Zákuciová M; D'Haens G; Van Assche G; Ba S; Lee S; Pearce T
    Gut; 2006 Aug; 55(8):1131-7. PubMed ID: 16507585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.